Dean has built up a wealth of knowledge on the global generics and biosimilar medicines industries since joining Generics Bulletin in 2013. He specializes in commercial and legal issues, writing in-depth analyses of corporate strategy and getting under the skin of patent infringement proceedings and other litigation. He attends investor and regulatory meetings with business leaders, favoring the investor days with their focus on corporate strategy. In his spare time, Dean enjoys visiting museums and playing five-a-side football.
Latest from Dean Rudge
Regeneron has taken a further swipe at Amgen after the biosimilars sponsor surprised the market by launching the first US rival to Eylea at-risk last month.
Dr Reddy’s Laboratories has spoken at length about its ability to make most of its GLP-1 APIs and formulations in-house, as it looks to be a ‘day one’ player for opportunities including semaglutide.
GLP-1 drugs like Ozempic and Mounjaro have shaken up pharma, crossing firmly over into the mainstream while netting fortunate suppliers billions of dollars in the process. As patent expiry approaches for first- and second-generation products, generics manufacturers are gearing up to take a share of the spoils.
Aurobindo is looking to finally put a key manufacturing disruption behind it in Europe, enabling the firm to gain traction for some of its early biosimilar filings.
Viatris provided several updates for its launch plans in 2025 during the company’s third-quarter earnings call.
Sandoz has ticked off a pair of corporate milestones, including the opening of a new UK device development center which will serve as a global hub for developing advanced delivery devices supporting the firm’s extensive pipeline.